This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

African-American Heart Failure Trial (A-HeFT), treatment with fixed-dose combined isosorbide dinitrate / hydralazine

Authoring team

In the African-American Heart Failure Trial (A-HeFT), treatment with fixed-dose combined isosorbide dinitrate/hydralazine (FDC I/H) added to neurohormonal blockade in patients with advanced HF resulted in:

  • a further 43% incremental reduction in mortality
  • a 39% reduction in heart failure hospitalizations
  • a 37% improvement in event-free survival, and significant improvement in quality of life (QoL)

Hydralazine-isosorbide dinitrate therapy is recommended for African American patients with moderate to severe heart failure with reduced ejection fraction (<40%) (HFrEF) (3).

Reference:

  1. Taylor AL et al. African-American Heart Failure Trial Investigators et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. NEJM (2004); 351:049-2057
  2. Taylor AL et al. African-American Heart Failure Trial Investigators et al. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine. Circulation (2007);115:1747-1753.
  3. Golwala HB. Use of hydralazine-isosorbide dinitrate combination in African American and other race/ethnic group patients with heart failure and reduced left ventricular ejection fraction.J Am Heart Assoc. 2013;21;2(4):

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.